Do MTRR rs1801394, BHMT rs3733890, and MTHFD1 rs2236225 variants predispose to higher homocysteine when B12 or folate are suboptimal?

One-carbon metabolism relies on a delicate balance of genetic enzymatic efficiency and nutritional cofactors to recycle homocysteine into methionine. When specific genetic variations are present, this metabolic flux is easily compromised under suboptimal nutrient conditions.

Molecular mechanisms of remethylation

• Enzymatic impairment: The MTRR rs1801394 (A66G) variant decreases methionine synthase reductase activity, directly hindering the recycling of vitamin B12 essential for the primary remethylation pathway.
• Folate intermediate restriction: The MTHFD1 rs2236225 polymorphism causes thermolability and reduces enzyme stability, limiting the generation of folate intermediates necessary for downstream reactions.
• Alternative pathway disruption: The BHMT rs3733890 variant alters the parallel, folate-independent pathway, which utilizes betaine as a methyl donor to convert homocysteine to methionine.

Nutritional modulation and homocysteine accumulation

• Cofactor dependency: Folate and vitamin B12 serve as critical substrates and cofactors. Suboptimal levels of these vitamins compound the catalytic limitations of the MTRR and MTHFD1 variant enzymes.
• Alternative methyl donors: Betaine and its precursor, choline, modulate overall remethylation capacity by fueling the parallel, folate-independent BHMT pathway.
• Clinical outcomes: Under conditions of folate or B12 insufficiency, carriers of these variants—especially MTHFD1 AA homozygotes or compound variant carriers—experience pronounced increases in plasma homocysteine due to restricted enzymatic capacity.

Bottom line

• Genetic variants in MTRR, BHMT, and MTHFD1 reduce catalytic efficiency across both folate-dependent and folate-independent pathways, predisposing individuals to elevated plasma homocysteine unless cofactor levels (B12, folate) and alternative methyl donors (betaine, choline) are optimized.